ATG Fresenius

DRUG4 trials

Conditions

Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated VolunteerRecipients of a Kidney From a Non-Heart-Beating DonorRenal Transplant PatientsRenal Transplant RejectionTransplantation, Kidney

Phase 3

Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor

NCT00733733

Radboud University Medical CenterRecipients of a Kidney From a Non-Heart-Beating Donor, Renal Transplant Patients

Start: 2008-01-31End: 2010-06-30Target: 180Updated: 2008-08-13

Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation

NCT00934557

Fondazione IRCCS Policlinico San Matteo di PaviaPaediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer

Start: 2008-03-31Target: 42Updated: 2009-07-08

Phase 4

Comparison of ATG to Thymoglobuline in Renal Transplantation

CompletedNCT00861536

University Hospital, Basel, SwitzerlandTransplantation, Kidney

Start: 2009-01-31End: 2015-02-28Updated: 2015-04-14

Simulect Versus ATG in Sensitized Renal Transplant Patient

CompletedNCT02377193

University Hospital, ToulouseRenal Transplant Rejection

Start: 2013-09-30End: 2017-01-31Updated: 2025-12-10

Related Papers

Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.

2017-07-1051 citations

Long-Term Results on Outcome of Children with Hematological Malignancies Transplanted from an Unrelated Donor Enrolled in an Open Label, Randomized Trial Comparing Two Different Dosages of Rabbit Anti-Thymocyte Globulin

Blood2016-12-02

ATG Fresenius

Sponsors

Conditions

Phase 3

Phase 4

Related Papers